ALT trade ideas
ALT a top gainer, rising +922.8%. Expect Uptrend continuationAltimmune (ALT, $31.4) was one of top quarterly gainers, jumping +922.8% to $31.4 per share. Tickeron A.I.dvisor analyzed 138 stocks in the Miscellaneous Commercial Services Industry over the last three months, and discovered that 120 of them (86.96%) charted an Uptrend while 18 of them (13.04%) trended down. Tickeron A.I.dvisor found 63 similar cases when ALT's price jumped over 15% within three months. In 38 out of those 63 cases, ALT's price went up during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend continuation for ALT are 60%.
ALT's in Uptrend: Moving Average Convergence Divergence (MACD) Histogram crosses above signal line
This is a Bullish indicator signaling ALT's price could rise. Traders may explore going long on the ticker or buying call options. Tickeron AI shows that in 24 of 28 cases where ALT's MACD histogram became positive, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Current price $29.03 is above $4.49 the highest resistance line found by Tickeron A.I. Throughout the month of 06/17/20 - 07/20/20, the price experienced a +330% Uptrend. During the week of 07/13/20 - 07/20/20, the stock enjoyed a +8% Uptrend growth.
Bullish Trend Analysis
The Momentum Indicator exceeded the 0 level on June 22, 2020. Traders may consider buying the ticker or exploring call options. Tickeron AI shows that in 43 of 51 cases where the ticker's Momentum Indicator exceeded 0, its price rose further within the subsequent month. The odds of a continued Uptrend are 84%
ALT Bullish At OpenHello everyone! You can see the full video review by clicking the link below in my signature description!
I have updated charts, and new video's every day. Follow me on tradingview, and subscribe to me on youtube!
Leave any questions or comments, and I will get back to you as soon!
$ALT Altimmune, Inc. on Breakout WatchAltimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.
ANALYST RATINGS
SELL
UNDER
HOLD
OVER
BUY
NUMBER OF RATINGS 1FULL RATINGS
Take the Profits w/ ALT and ShortFirst off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. The bull run went too high in my opinion and the current wedge looks like it can receive some steep resistance. I think right now it is at a good level where it is a better idea to not try getting too greedy because just as it went up really high, it can also come crashing down steeply as well. Anyways, proceed with caution. If you like this, it is probably less risky to sell and than rebuy at the dip rather than hold long at this current level.
Completes First Development Milestone Toward A Single-DoseFeb. 28, 2020 announced the advancement of a novel single-dose, intranasal vaccine using Altimmune’s proprietary technology to protect against COVID-19, the disease caused by the SARS-CoV-2 virus. Altimmune has completed the design and synthesis of the vaccine and is now advancing it toward animal testing and manufacturing.
the COVID-19 vaccine is designed to provide systemic immunity following a single intranasal dose.
A recent Phase 2 clinical study with NasoVAX highlighted the ability of intranasal vaccine delivery to stimulate a durable and broad immune response against the influenza virus.
ir.altimmune.com
Altimmune, Inc. Jumps On Vaccine NewsAltimmune, Inc. is a clinical stage immunotherapeutic biotechnology company, which is focused on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. Its portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
ANALYST RATINGS
SELL
UNDER
HOLD
OVER
BUY
NUMBER OF RATINGS 1FULL RATINGS
